(MENAFN- GlobeNewsWire - Nasdaq) NEW YORK, July 19, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Pardes Biosciences, Inc. (NASDAQ: PRDS) 's sale to MediPacific, Inc. Per the terms of the agreement, MediPacific would acquire all outstanding shares of Pardes for not less than $2.02 in cash and an additional cash amount of not more than $0.17 per share at closing, plus a non-tradeable contingent value right representing the right to receive 80% of the net proceeds payable from any license or disposition of Pardes' programs and assets effected within five years of closing. If you are a Pardes shareholder, click here to learn more about your rights and options .
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX) 's merger with Neurogene Inc. Pre-merger Neoleukin stockholders are expected to own approximately 16% of the combined company. If you are a Neoleukin shareholder, click here to learn more about your rights and options .
Kaleyra, Inc. (NYSE: KLR ) 's sale to Tata Communications for $7.25 per share. If you are a Kaleyra shareholder, click here to learn more about your rights and options .
Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email or .
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
Tags class action
MENAFN19072023004107003653ID1106627229
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.